Silence Therapeutics plc (SLNCF)

Market Cap	148.29M
Revenue (ttm)	43.26M
Net Income (ttm)	-45.31M
Shares Out	n/a
EPS (ttm)	-0.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,000
Average Volume	14,300
Open	0.8000
Previous Close	0.4986
Day's Range	0.8000 - 0.9500
52-Week Range	0.4986 - 14.7500
Beta	1.25
RSI	46.64
Earnings Date	May 15, 2025

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 116
• Stock Exchange: OTCMKTS
• Ticker Symbol: SLNCF

Financial Performance

In 2024, Silence Therapeutics's revenue was $43.26 million, an increase of 36.71% compared to the previous year's $31.64 million. Losses were -$45.31 million, -16.45% less than in 2023.